DXCM Live signals | Maximize Profits with Getagraph.com

BUY 871 min ago

@ $137.94

Issued: 25 Apr 2024 @ 15:42

Return: 0.05%

Previous signal: Apr 25 - 12:41

Previous signal: Sell

Return: 0.81 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally...

Stats
Today's Volume	4.16M
Average Volume	3.08M
Market Cap	53.20B
EPS	$0 ( 2024-04-25 )
Next earnings date	( $0.270 ) 2024-07-25
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	106.16
ATR14	$4.79 (3.47%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-15	Dolan Matthew Vincent	Sell	1 990	Common Stock
2024-04-08	Sayer Kevin R	Sell	27 272	Common Stock
2024-04-08	Sayer Kevin R	Sell	22 361	Common Stock
2024-03-28	Brown Michael Jon	Sell	2 524	Common Stock
2024-03-28	Brown Michael Jon	Sell	100	Common Stock

INSIDER POWER
-3.99
Last 99 transactions
Buy: 330 077 \| Sell: 354 468

Volume Correlation

Long: -0.17 (neutral)

Short: -0.01 (neutral)

Signal:(43) Neutral

DexCom Inc Correlation

10 Most Positive Correlations
SVBI	0.821
BOSC	0.807

10 Most Negative Correlations
QTEK	-0.802

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

DexCom Inc Correlation - Currency/Commodity

0.26
( neutral )

0.30
( neutral )

0.00
( neutral )

0.27
( neutral )

0.10
( neutral )

-0.55
( weak negative )

DexCom Inc Financials

Annual	2023
Revenue:	$3.62B
Gross Profit:	$2.29B (63.19 %)
EPS:	$1.400

FY	2023
Revenue:	$3.62B
Gross Profit:	$2.29B (63.19 %)
EPS:	$1.400

FY	2022
Revenue:	$2.91B
Gross Profit:	$1.88B (64.72 %)
EPS:	$0.880

FY	2021
Revenue:	$2.45B
Gross Profit:	$1.68B (68.63 %)
EPS:	$0.400

Financial Reports:

No articles found.

DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.